Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 67,608 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $5.00, for a total value of $338,040.00. Following the completion of the sale, the chief executive officer now owns 15,007,816 shares in the company, valued at $75,039,080. The trade was a 0.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
David Zaccardelli also recently made the following trade(s):
- On Friday, December 6th, David Zaccardelli sold 162,800 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total value of $815,628.00.
- On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total value of $16,000.00.
- On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total value of $495,428.88.
- On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total value of $116,200.00.
- On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $12,000.00.
- On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total value of $413,292.16.
- On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $205,369.44.
- On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
- On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
- On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $483,797.28.
Verona Pharma Stock Performance
Verona Pharma stock traded up $0.48 during trading on Friday, reaching $40.50. The company had a trading volume of 626,985 shares, compared to its average volume of 939,445. Verona Pharma plc has a 52 week low of $11.39 and a 52 week high of $40.76. The firm's 50-day simple moving average is $35.74 and its 200 day simple moving average is $26.18. The firm has a market capitalization of $3.31 billion, a price-to-earnings ratio of -21.09 and a beta of 0.46. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). The company had revenue of $5.62 million during the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. Sell-side analysts forecast that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently issued reports on VRNA. Wells Fargo & Company raised their price target on Verona Pharma from $50.00 to $64.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. HC Wainwright raised their price target on Verona Pharma from $36.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Truist Financial raised their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. Finally, Canaccord Genuity Group raised their price target on Verona Pharma from $37.00 to $44.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $43.83.
Check Out Our Latest Stock Report on Verona Pharma
Hedge Funds Weigh In On Verona Pharma
A number of institutional investors have recently bought and sold shares of VRNA. CWM LLC bought a new stake in Verona Pharma during the second quarter valued at about $29,000. Hennion & Walsh Asset Management Inc. raised its holdings in Verona Pharma by 101.3% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 135,629 shares of the company's stock valued at $1,961,000 after acquiring an additional 68,264 shares during the period. AMI Asset Management Corp bought a new stake in Verona Pharma during the second quarter valued at about $1,012,000. Legato Capital Management LLC bought a new stake in Verona Pharma during the second quarter valued at about $154,000. Finally, EMC Capital Management bought a new stake in Verona Pharma during the second quarter valued at about $38,000. 85.88% of the stock is owned by institutional investors.
Verona Pharma Company Profile
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
![Insider Buying and Selling by Quarter for Verona Pharma (NASDAQ:VRNA)](https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&Symbol=VRNA)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.